title: Recommendations for amniocentesis in HIV-positive women.
abstract: There is limited literature on the known risk of HIV transmission during amniocentesis. Before the introduction of highly active antiretroviral therapy (HAART), amniocentesis was avoided owing to the increased risk of HIV transmission. Recent literature suggests that it is safe to perform amniocentesis in women on HAART with undetectable viral loads. In South Africa (SA), many women access antenatal care late in pregnancy and there is often insufficient time to attain undetectable viral loads within a pre-viability period. Guidelines and recommendations for invasive testing in HIV-positive women in the SA setting are lacking. This article provides recommendations to healthcare practitioners who are faced with an HIV-positive patient requiring amniocentesis.
authors.forename: S N
authors.initials: SN
authors.lastname: Constantatos
authors.forename: A H
authors.initials: AH
authors.lastname: Boutall
authors.forename: C J
authors.initials: CJ
authors.lastname: Stewart
mesh_terms: D000649:Amniocentesis / Q000009:adverse effects / Q000379:methods*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D012306:Risk; D013019:South Africa; D019562:Viral Load